Flow Traders U.S.’s TherapeuticsMD TXMD Stock Holding History

Flow Traders U.S.’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-2,493	Closed	-$378K	–	303
2013 Q2	$378K	Buy	+2,493	New	+$342K	0.11%	62

Other funds holding TXMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flow Traders U.S.'s TXMD Position: Q3 2013 in Review

Flow Traders U.S. sold out of TherapeuticsMD (TXMD) in Q3 2013, closing a stake of 2,493 shares — an estimated $378K sold.

Flow Traders U.S. first reported a position in TXMD in Q2 2013 and held it in 1 quarter. The position peaked at $378K in Q2 2013. 53 funds tracked by Wall St. Rank hold TXMD as of Q3 2013.

Flow Traders U.S. reported no remaining TherapeuticsMD position as of Q3 2013 after selling out during the quarter.
Flow Traders U.S. sold 2,493 TherapeuticsMD shares in Q3 2013, an estimated $378K.
Flow Traders U.S. first reported a position in TherapeuticsMD in Q2 2013 and held it in 1 quarter.
Flow Traders U.S.'s TherapeuticsMD position peaked at $378K in Q2 2013.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2013.

Based on Flow Traders U.S.'s 13F filing for Q3 2013, filed 14 Nov 2013.